An updated patent review of p38 MAP kinase inhibitors (2014-2019)

References

• Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005 Jan 1;15(1):11–18.
   PubMed Web of Science ®Google Scholar
• Cuadrado a, Nebreda Angel R. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403–417.
   PubMed Web of Science ®Google Scholar
• Corre I, Paris F, Huot J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget. 2017;8(33):55684–55714.
   PubMedGoogle Scholar
• Ferrari G, Terushkin V, Wolff MJ, et al. TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38β to proapoptotic p38α. Mol Cancer Res. 2012;10(5):605–614.
   PubMed Web of Science ®Google Scholar
• Stramucci L, Pranteda a, Stravato a, et al.. MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer. Cell Death Dis. 2019 Nov 06;10(11):842.
   PubMedGoogle Scholar
• p38 Signaling Interactive Pathway. [cited 2020 Mar 2]. Available from: https://www.novusbio.com/p38mapkpathway.html
   Google Scholar
• Bühler S, Laufer SA. p38 MAPK inhibitors: a patent review (2012 – 2013). Expert Opin Ther Pat. 2014 May 01; 24(5):535–554.
   PubMed Web of Science ®Google Scholar
• Fischer S, Koeberle SC, Laufer SA. p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011). Expert Opin Ther Pat. 2011 Dec 1;21(12):1843–1866.
   PubMed Web of Science ®Google Scholar
• Lee JC, Laydon JT, McDonnell PC, et al.. a protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994 Dec 1;372(6508):739–746.
   PubMed Web of Science ®Google Scholar
• EIP Pharma, LLC. Compositions and methods for treating dementia. WO2017185073A1. 2017.
   Google Scholar
• ChemIDplus. CHF-6297. [cited 2019 Dec 19]. Available from: https://chem.nlm.nih.gov
   Google Scholar
• Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl 1):i77.
   PubMed Web of Science ®Google Scholar
• Lea S, Li J, Plumb J, et al.. P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells. J Mol Med. 2020 Jan 23;98(3):361–374.
   PubMed Web of Science ®Google Scholar
• City Of Hope. P38 gamma inhibitors and method of use thereof. WO2018191171A1. 2018.
   Google Scholar
• Fundacio Institut de Recerca Biomedica Irb Barcelona, Institucio Catalana de Recerca I Estudis Avancats. Composition comprising a specific p38α inhibitor and an agent that induces chromosome instability and medical uses thereof in treatment of breast cancer. WO2018229057A1. 2018.
   Google Scholar
• The General Hospital Corporation. Combination chemotherapy with p38 MAPK inhibitors for reducing chemoresistance in acute myelogenous leukemia. WO2018183559A1. 2018.
   Google Scholar
• Menon MB, Gropengießer J, Fischer J, et al.. p38MAPK/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat Cell Biol. 2017 Oct 1;19(10):1248–1259.
   PubMed Web of Science ®Google Scholar
• Allinky Biopharma. p38 MAPK inhibitors for the treatment of inflammatory diseases. WO2014094816A1. 2014.
   Google Scholar
• Fabbro D, Cowan-Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol. 2015;172(11):2675–2700. .
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng -T-T, Chindalore V, et al.et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheumatism. 2009;60(2):335–344.
   PubMed Web of Science ®Google Scholar
• Walter NM, Wentsch HK, Bührmann M, et al.. Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. J Med Chem. 2017 Dec 12;60(19):8027–8054.
   PubMed Web of Science ®Google Scholar
• Wentsch HK, Walter NM, Bührmann M, et al. Optimized Target Residence Time: type I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine. Angewandte Chemie. 2017;56(19):5363–5367.
   Google Scholar
• Genovese M, Cohen S, Wofsy D, et al. A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. J Rheumatol. 2011;38(5):846–854.
   PubMed Web of Science ®Google Scholar
• Martz KE, Dorn a, Baur B, et al.. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors. J Med Chem. 2012 Sep 13;55(17):7862–7874.
   PubMed Web of Science ®Google Scholar
• Allinky Biopharma. p38 and JNK MAPK inhibitors for the treatment and prophylaxis of degenerative diseases of the nervous system. WO2015193281A1. 2015.
   Google Scholar
• Gomez-Gutierrez P, Campos PM, Vega M, et al. Identification of a novel inhibitory allosteric site in p38α. PloS One. 2016;11(11):e0167379.
   PubMed Web of Science ®Google Scholar
• Ter Haar E, Prabakhar P, Liu X, et al. Crystal structure of the p38α-MAPKAP kinase 2 heterodimer. J Biol Chem. 2007;282(13):9733–9739.
   PubMed Web of Science ®Google Scholar
• Tanoue T, Maeda R, Adachi M, et al. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. Embo J. 2001;20(3):466–479.
   PubMed Web of Science ®Google Scholar
• Willemen HLDM, Campos PM, Lucas E, et al.et al. A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia. Biochem J. 2014;459(3):427–439.
   PubMedGoogle Scholar
• Chiesi Farmaceutici S.p.a.. Preparation of fused bicyclic compounds as p38 MAPK inhibitors. WO2014195402A1. 2014.
   Google Scholar
• Chiesi Farmaceutici S.p.a. Preparation of 1-(3-tert-butyl-2H-pyrazol-5-yl) or (5-tert-butylisoxaol-3-yl)-3-[4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea compounds useful as P38α kinase inhibitors for the treatment of respiratory disease. WO2017108738A1. 2017
   Google Scholar
• Chiesi Farmaceutici S.p.a.. Preparation of 1-(3-tert-butylphenyl)-3-[4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea compounds useful as P38α kinase inhibitors for the treatment of respiratory disease. WO2017108737A1. 2017.
   Google Scholar
• Chiesi Farmaceutici S.p.a. Preparation of N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38α MAP kinase inhibitors. WO2017108736A1. 2017.
   Google Scholar
• Chiesi Farmaceutici S.p.a. Prepn. of 4-(([1,2,4]triazolo[4,3-a]pyridine-6-yl) oxy)-1,2,3,4-tetrahydronaphthalen-1-yl)ureido derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases of respiratory tract. WO2018224423A1. 2018.
   Google Scholar
• Martucci a, Moretto N, Aquino G, et al.. CHF-6297, a Novel Selective p38α (MAPK14) Inhibitor designed for inhalation delivery, effectively counteracts IL-1β-evoked acute lung inflammation. C74. ADVANCES IN TRANSLATIONAL COPD. 2017 May 1;A6330-A30.
   Google Scholar
• AdisInsight, Drug profile CHF 6297. [cited 2020 Jan 3]. Available from: https://adisinsight.springer.com/
   Google Scholar
• Ltd. T. Our Origins. [cited 2020 Jan 20]. Available from: http://www.topivert.com/our-origins
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors. WO2016051186A1. 2016.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Diaryl urea derivatives as p38 kinase inhibitors. WO2016051187A1. 2016.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Pyrazolyl-ureas as kinase Inhibitors. WO2014027209A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Pyrazole derivatives as p38 map inhibitors. WO2014033448A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitors. WO2014140582A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitors based upon n-alkyl pyrazoles. WO2014162121A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitor. WO2014162122A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. 4-(4-(4-phenylureido-naphthalen-1-yl)oxy-pyridin-2-yl)amino-benzoic acid derivative as p38 kinase inhibitor. WO2016051188A1. 2016.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitors. WO2014033446A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd, assignee. Kinase inhibitors patent. WO2014033449A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitors. WO2014076484A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Diaryl urea derivatives as p38 MAP kinase inhibitors. WO2014033447A3. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Urea derivatives useful as kinase inhibitors. WO2014162126A1. 2014.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Pyrazolyl-ureas as kinase inhibitors. WO2015121660A1. 2015.
   Google Scholar
• TopiVert Pharma Ltd, RespiVert Ltd. Kinase inhibitors. WO2017174995A1. 2017.
   Google Scholar
• TopiVert Pharma Ltd, RespVert Ltd. Urea derivatives useful as kinase inhibitors. WO2015092423A1. 2015.
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/results?term=TOP1288&draw=2&rank=2#rowId1
   Google Scholar
• TopiVert. [cited 2020 Jan 20]. Available from: http://www.topivert.com/top1630-for-ded
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=TOP1630&cntry=&state=&city=&dist=
   Google Scholar
• Torrent Pharmaceuticals Limited. Novel fused imidazobenzothiazole compounds. WO2015145336A1. 2015.
   Google Scholar
• Torrent Pharmaceuticals Limited. P38 map kinase inhibiting indanyl urea compounds. WO2016030852A1. 2016.
   Google Scholar
• Angell RM, Angell TD, Bamborough P, et al.. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433–4437.
   PubMed Web of Science ®Google Scholar
• Fitzgerald CE, Patel SB, Becker JW, et al.. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Mol Biol. 2003 Sep 1;10(9):764–769.
   Google Scholar
• Confluence Life Sciences. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds. WO2014197846A1. 2014.
   Google Scholar
• Wang C, Hockerman S, Jacobsen EJ, et al.. Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315–1325.
   PubMed Web of Science ®Google Scholar
• Aclaris Therapeutics. [cited 2019 Jan 7]. Available from: https://www.sec.gov/Archives/edgar/data/1557746/000155837019008709/ex-99d1.htm
   Google Scholar
• Hope Co. Research. [cited 2020 Jan 20]. Available from: https://www.cityofhope.org/research
   Google Scholar
• Integral Biosciences Private Limited. Preparation of fused heterocycles, especially substituted 1H-pyrrolo[2,3-b]pyridines, as dual inhibitors of ALK5 and P38α MAP kinase. WO2019142128A1. 2019.
   Google Scholar
• Korcsmáros T, Szalay MS, Böde C, et al.. How to design multi-target drugs. Expert Opin Drug Discov. 2007 Jun 1;2(6):799–808.
   PubMed Web of Science ®Google Scholar
• Gui T, Sun Y, Shimokado a, et al. The roles of mitogen-activated protein kinase pathways in TGF-β-induced epithelial-mesenchymal transition. J Signal Transduct. 2012;2012:1–10.
   PubMedGoogle Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–165.
   PubMed Web of Science ®Google Scholar
• Hwang ST, Janik JE, Jaffe ES, et al.. Mycosis fungoides and Sézary syndrome. Lancet. 2008 Mar 15;371(9616):945–957.
   PubMed Web of Science ®Google Scholar
• Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol. 2006 Feb 1;33:3–6.
   Web of Science ®Google Scholar
• University of Maryland, United States Dept. of Veterans Affairs Office of General Counsel. Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof. WO2017223284A1. 2017.
   Google Scholar
• Koeberle SC, Romir J, Fischer S, et al.. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol. 2012 Feb 1;8(2):141–143.
   Web of Science ®Google Scholar
• Shah NG, Tulapurkar ME, Ramarathnam a, et al. Novel noncatalytic substrate-selective p38α-Specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity. J Immunol. 2017;198(8):3296–3306.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of Michigan. Preparation of dual Src/p38 kinase inhibitor compounds and their use as therapeutic agents. WO2017087818A1. 2017.
   Google Scholar
• Hvivo Services Limited. Methods and p38 MAPK inhibitor compounds for the treatment or prevention of hypercytokinemia and severe influenza. WO2019122909A1. 2019.
   Google Scholar
• Strekin AG. Methods of preventing or treating ophthalmic diseases using combination of peroxisome proliferator-activated receptor (PPAR) agonists and p38 MAP kinase inhibitors. WO2018185098A1. 2018.
   Google Scholar
• Albany Medical College. Treatment of Rosacea with p38MAPK and ERK kinase pathway inhibitors. WO2017192928A1. 2017.
   Google Scholar
• GlaxoSmithKline Intellectual Property No.2 Limited. Losmapimod for use in treating glomerular disease. WO2015004089A1. 2015.
   Google Scholar
• Fulcrum Therapeutics. Use of p38 inhibitors to reduce expression of DUX4. WO2019071144A1. 2019.
   Google Scholar
• Globenewswire, fulcrum therapeutics announced results of phase 1 clinical trial of losmapimod in FSHD. [cited 2020 Jan 9]. Available from: https://www.globenewswire.com
   Google Scholar
• The Doshisha. Drug for treating or preventing disorder caused by corneal endothelial TGF-β signaling and its application by using p38 MAP kinase inhibitor. WO2019022152A1. 2019.
   Google Scholar
• The Trustees of the University of Pennsylvania. P38 MAP kinase inhibitors for treating Friedreich’s ataxia. WO2016154329A2. 2016.
   Google Scholar